WIB22: Lead­ing NK cell re­searcher re­flects on roots in Iran, the UK and Texas

This pro­file is part of End­points News’ 2022 spe­cial re­port about Women in Bio­phar­ma R&D. You can read the full re­port here.

In a small but wide­ly-cit­ed 11-per­son study pub­lished in NE­JM in 2020, sev­en pa­tients saw signs of their can­cer com­plete­ly go away af­ter get­ting a new ther­a­py made from nat­ur­al killer cells. The study was one of the ear­li­est to pro­vide clin­i­cal proof that the ex­per­i­men­tal treat­ment method had promise.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN